The purpose of this study is to determine if EGFR status (positive or negative) by FISH can predict response to cetuximab therapy in NSCLC patients treated with carboplatin and paclitaxel

Inclusion Criteria:

• Subjects who present with Stage IV, Stage IIIB NSCLC or recurrent disease following radiation therapy or surgical resection
• No prior chemotherapy or anti-EGFR targeted therapy
• Sufficient tumor material for FISH testing
• Measurable disease (RECIST)
• ECOG performance status 0 or 1

Exclusion Criteria:

• Symptomatic or uncontrolled CNS metastases
• Inadequate hematologic function defined as ANC < 1,500/mm3, platelet count < 100,000/mm3, or a hemoglobin level < 9 g/dl
• Inadequate hepatic function defined as total bilirubin > 1.25 x ULN, AST level > 1.5 x ULN, or alkaline phosphatase > 5.0 x ULN
• Inadequate renal function defined by a serum creatinine level > 1.5 x ULN